Li Zhao

Li Zhao

Auto-generated profile, based on publicly available information

Li Zhao

Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
JJJuan Jin
Juan Jin
YSYifen Shi
Yifen Shi
JGJianguang Gong
Jianguang Gong
LZLi Zhao
Li Zhao
YLYiwen Li
Yiwen Li
HHHe Huang
He Huang
It is confirmed that adipose-derived stem cells (ADSCs) transplantation effectively relieves kidney fibrosis and type 2 diabetes disease in mice. Currently, exosome from urine-derived stem cells (USCs) can protect type 1 diabetes-mediated kidney injury and attenuate podocyte damage in diabetic nephropathy (DN). Exosome derived from USCs has evolved into the strategy for DN treatment, but the role of ADSCs-derived exosome (ADSCs-Exo) in DN remains unclear. The present study is aimed to investigate the therapeutic action and molecular mechanism of ADSCs-derived exosome on DN. ADSCs and exosome were authenticated by immunofluorescence and flow cytometry. Morphology and the number of exosome were evaluated by electron microscope and Nanosight Tracking Analysis (NTA), respectively. Cell apoptosis was assessed using flow cytometry. Podocyte autophagy and signaling transduction were measured by immunofluorescence and immunoblotting. Dual Luciferase Reporter assay was employed to detect the regulatory relationship between miR-486 and Smad1. ADSCs-Exo attenuated spontaneous diabetes by reducing levels of urine protein, serum creatinine (Scr), blood urea nitrogen (BUN), and podocyte apoptosis in mice. In in vitro experiment, ADSCs-Exo also reversed high glucose-induced decrease of cell viability and the increase of cell apoptosis in MPC5 cells. In terms of mechanism, ADSCs-Exo could enhance autophagy flux and reduce podocyte injury by inhibiting the activation of mTOR signaling in MPC5 and spontaneous diabetic mice. Eventually, we found that miR-486 was the key factors in ADSCs and in the process of ADSCs-Exo-mediated improvement of DN symptom in vivo and in vitro. miR-486 reduced Smad1 expression by target regulating Smad1 whose reduction could inhibit mTOR activation, leading to the increase of autophagy and the reduction of podocyte apoptosis. In conclusion, we illustrated that ADSCs-Exo vividly ameliorated DN symptom by enhancing the expression of miR-486 which led to the inhibition of Smad1/mTOR signaling pathway in podocyte. Possibly, ADSCs-Exo was used as a main therapeutic strategy for DN in future.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JJJuan Jin
Juan Jin
YWYunguang Wang
Yunguang Wang
LZLi Zhao
Li Zhao
WZWenli Zou
Wenli Zou
MTMingming Tan
Mingming Tan
QHQiang He
Qiang He
Background. Podocyte migration is actively involved in the process of podocyte loss and proteinuria production, which is closely associated with the development of diabetic nephropathy (DN). Exosomes from adipose‐derived stem cells (ADSCs‐Exos) effectively inhibit podocyte apoptosis in the treatment of DN. However, how ADSCs‐Exos affect the migration of podocytes is obscure. This study is aimed at exploring the regulatory role of ADSCs‐Exos on cell migration and the underlying mechanism. Methods. ADSCs‐Exo was authenticated by transmission electron microscopy (TEM), western blotting, and flow cytometry. Cell viability and migration ability of podocytes were measured by CCK8 and Transwell assays, respectively. Relative expressions of miRNAs and mRNAs were determined by qRT‐PCR. The transmitting between PKH26‐labeled exosome and podocytes was evaluated by IF assay. Dual luciferase reporter assay was employed to detect the relationship between miR‐215‐5p and ZEB2. Results. The exposure to serum from DN patient (hDN‐serum) significantly inhibited cell viability of podocytes, but ADSCs‐Exo addition notably blunts cytotoxicity induced by the transient stimulus of hDN‐serum. Besides, ADSCs‐Exo administration powerfully impeded high glucose‐ (HG‐) induced migration and injury of podocyte. With the podocyte dysfunction, several miRNAs presented a significant decline under the treatment of HG including miR‐251‐5p, miR‐879‐5p, miR‐3066‐5p, and miR‐7a‐5p, all of which were rescued by the addition of ADSCs‐Exo. However, only miR‐251‐5p was a key determinant in the process of ADSCs‐Exo‐mediated protective role on podocyte damage. The miR‐251‐5p inhibitor counteracted the improvement from the ADSCs‐Exo preparation on HG‐induced proliferation inhibition and migration promotion. Additionally, miR‐215‐5p mimics alone remarkably reversed HG‐induced EMT process of podocyte. Mechanistically, we confirmed that ADSCs‐Exos mediated the shuttling of miR‐215‐5p to podocyte, thereby protecting against HG‐induced metastasis, possibly through inhibiting the transcription of ZEB2. Conclusion. ADSCs‐Exo has the protective effect on HG‐evoked EMT progression of podocytes thru a mechanism involving ZEB2. Potentially, the ADSCs‐Exo preparation is a useful therapeutic strategy for improving podocyte dysfunction and DN symptoms clinically.

4 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JJJuan Jin
Juan Jin
FCFen Chen
Fen Chen
WHWenfang He
Wenfang He
LZLi Zhao
Li Zhao
BLBo Lin
Bo Lin
QHQiang He
Qiang He
Aberrant epigenetic reprogramming contributes to the progression of renal cell carcinoma (RCC). Elucidation of key regulators of epigenetic reprogramming in RCC could help identify therapeutic vulnerabilities to improve treatment. Here, we report upregulation of the nuclear matrix-associated protein, special AT-rich binding protein-2 (SATB2), in RCC samples, which correlated with poor prognosis. SATB2 inhibition suppressed RCC growth and self-renewal capacities. YAP/TEAD4 activated SATB2 expression and depended on SATB2 to enhance cell proliferation. Transcriptome analysis implicated that SATB2 regulates NRF2 downstream targets to suppress oxidative stress without altering NRF2 levels. Integrated chromatin immunoprecipitation sequencing and assay for transposase-accessible chromatin using sequencing analyses demonstrated that SATB2 coordinated with NRF2 to drive enhancer–promoter interactions, amplifying transcriptional activity. SATB2 recruited SWI/SNF complex subunits, including BRD7 or BRG1, to sustain DNA accessibility. Increased SATB2 triggered chromatin remodeling into configurations that rendered RCC more sensitive to SATB2 deficiency. Moreover, SATB2 ablation promoted the sensitivity of RCC to chemotherapy-induced apoptosis. Finally, targeting SATB2 or BRD7 effectively restricted the proliferation of YAP-high tumors in patient-derived xenografts and patient-derived organoids. Together, SATB2 is an oncogenic chromatin organizer in RCC, and targeting SATB2 is an effective strategy to suppress the YAP-high RCC. Significance: A YAP-SATB2-NRF2 regulatory axis amplifies antioxidative stress signaling and provides potential therapeutic targets to enhance response to chemotherapy in renal cell carcinoma.